Aims/hypothesis Angiotensin II is well-recognised to be a key mediator in driving the pathological events of diabetesassociated atherosclerosis via signalling through its angiotensin II type 1 receptor (AT 1 R) subtype. However, its actions via the angiotensin II type 2 receptor (AT 2 R) subtype are still poorly understood. This study is the first to investigate the role of the novel selective AT 2 R agonist, Compound 21 (C21) in an experimental model of diabetes-associated atherosclerosis (DAA). Methods Streptozotocin-induced diabetic Apoe-knockout mice were treated with vehicle (0.1 mol/l citrate buffer), C21 (1 mg/kg per day), candesartan cilexetil (4 mg/kg per day) or C21 + candesartan cilexetil over a 20 week period. In vitro models of DAA using human aortic endothelial cells and monocyte cultures treated with C21 were also performed. At the end of the experiments, assessment of plaque content and markers of oxidative stress, inflammation and fibrosis were conducted.
Introduction
Overactivation of the renin-angiotensin system (RAS) is wellrecognised to be a major underlying pathological mechanism that drives the development of diabetic vascular disease, with its effector peptide, angiotensin II (Ang II), being the main mediator [1] . Pharmacological inhibition of the RAS by targeting either Ang II production with an angiotensinconverting enzyme inhibitor or the activity of Ang II with an angiotensin receptor blocker (ARB) remains first-line treatment for patients with diabetes and vascular disease [2] . However, it has been proposed that the beneficial effects of these treatments are out of proportion with the magnitude of blood pressure reduction, suggesting more direct effects on end organs, including the macrovasculature.
Although Ang II binds with similar affinity to both the AT 1 and AT 2 receptor subtypes [3] , the relative importance of these receptors in modulating vascular injury remains poorly understood. Angiotensin II type 1 receptors (AT 1 Rs) are primarily involved in mediating the pathophysiological actions of Ang II, including its ability to regulate blood pressure, vasoconstriction and cellular differentiation and promote hypertrophy [4] . Strikingly, Ang II negatively regulates its classical actions through the angiotensin II type 2 receptors (AT 2 Rs) [5] , with this receptor subtype being markedly upregulated in numerous diseased states, including atherosclerosis [6, 7] , possibly to counterbalance the adverse effects mediated by the AT 1 R. Taken together, these actions highlight the potential of the AT 2 R as a key therapeutic target. With numerous studies focusing on the role of the AT 2 R in the non-diabetes setting [8] [9] [10] , the vascular actions of this receptor in the context of diabetes still remains unclear. Given our previous findings that selective activation of the AT 2 R by a novel non-peptide agonist, Compound 21 (C21), significantly ameliorated the progression of nephropathy in an insulin-deficient model [11] , we aimed to further investigate the protective role of C21 on macrovascular disease in this diabetes model. C21 is a highly specific AT 2 R agonist, with a K i value of 0.4 nmol/l and >1000 nmol/l for the AT 2 R and AT 1 R, respectively [12] . This study is the first to delineate the vasoprotective role of C21 in an experimental model of streptozotocin (STZ)-induced insulin-deficient diabetes in vivo, followed by extension of the findings to explore potential underlying mechanisms in vitro.
Methods
Animals Male apolipoprotein E-knockout (Apoe −/− ) mice on a C57BL6/J background (Jackson Laboratory, Sacramento, CA, USA) were used throughout the study based on previous findings that the mice in this model develop accelerated DAA upon the induction of diabetes and so constitute an appropriate model of DAA [13] . Mice were housed and maintained on a 12 h light-dark cycle in a pathogen-free environment and had free access to water and rodent lab chow (Specialty Feeds, Glen Forrest, WA, Australia). Experiments were conducted in accordance with the Australian code of practice for the care and use of laboratory animals for scientific purposes.
In vivo experimental procedure Seven-week-old Apoe −/− mice were rendered diabetic via a daily intraperitoneal injection of STZ (Sigma-Aldrich, St Louis, MO, USA) at a dose of 55 mg/kg per day over a period of 5 days. Animals with blood glucose and HbA 1c levels greater than 15 mmol/l and 10% (85.8 mmol/mol), respectively, after 10 days post-STZ-administration, were included in the study as diabetic. Diabetic mice were randomised and treated with vehicle (0.1 mol/l citrate buffer), C21 (1 mg/kg per day; Vicore Pharma, Göteborg, Sweden), the AT 1 R antagonist candesartan cilexetil (4 mg/kg per day; AstraZeneca Södertälje, Sweden) or C21 + candesartan treatment, via daily gavaging, over a 20 week period. These concentrations of C21 and candesartan had previously been shown to successfully ameliorate diabetic nephropathy [11, 14] . Non-diabetic mice treated in the absence or presence of C21 were also studied. At the end of the study, mice were killed and aortic tissues were excised for analysis. For assessment of body weight, metabolic variables and blood pressure, mice were placed in individual metabolic cages (Iffa Credo, L'Arbresele, France) for a period of 24 h and performed as described [11] .
Cell culture The atherosclerotic properties of the AT 2 R were further investigated in human aortic endothelial cells (HAEC) and monocyte cultures (THP-1) (obtained from ATCC, Manassas, VA, USA). Experiments were performed three or four separate times in duplicate. Cells were regularly tested for mycoplasma contamination by the media services (Baker IDI Heart and Diabetes Institute, Australia).
HAECs were cultured in endothelial growth media supplemented with EGM-2 Bulletkit (Lonza, Allendale, NJ, USA). In all experiments, EGM-2 media containing 5.6 mmol/l glucose was used as the normal-glucose condition, while EGM-2 media containing 25 mmol/l glucose (Sigma-Aldrich) was used as high-glucose condition.
THP-1 cells were maintained in RPMI supplemented with 10% fetal calf serum, penicillin (50 U/ml) and streptomycin (50 μg/ml). To induce monocyte-macrophage differentiation, cells were treated with phorbol-12-myristate-13-acetate (1 μmol/l; Sigma-Aldrich) 3 days before subjecting the cells to the various treatments.
In vitro experimental procedure To determine the optimal dose of C21, HAEC and THP-1 cultures (tested negative for mycoplasma contamination) were seeded into 12-well plates at equal density (1 × 10 5 to 1.5 × 10 5 cells/well) and treated with C21 (0.1-1.0 μmol/l) in both normal-(5 mmol/l) and highglucose (25 mmol/l) conditions for 72 h. Additional studies were also conducted to determine the following: (1) whether the optimal dose at which C21 inhibited high-glucosestimulated inflammatory and fibrotic markers was able to inhibit Ang II-mediated activity; (2) whether the ability of C21 to mediate this activity occurred specifically through the AT 2 R, by ascertaining whether C21-induced effects in these cells were blocked by the AT 2 R antagonist PD123319 (5 μmol/l; Cayman Chemical, Ann Arbour, MI, USA), (3) whether C21 as a combination therapy with an AT 1 R blocker, candesartan cilexetil (10 μmol/l) had any additive effect in attenuating DAA and (4) whether the candesartan cilexetilmediated effects were altered by PD123319. At the end of each experiment, RNA and protein were extracted from the cell layer with Trizol reagent (Life Technologies, Rockville, MD, USA) for subsequent analysis.
Evaluation of atherosclerotic plaque size and content Plaque area was quantified in an en face manner, as described previously [15] . Total and segmental plaque areas were quantified as a percentage area of aorta stained (Adobe Photoshop, version 7.0; Adobe Systems, Chatswood, NSW, Australia). Frozen sections of aortic sinus were stained with Oil Red O solution (Sigma-Aldrich) for 1 h followed by counterstaining with haematoxylin. Measurement of necrotic cores was subsequently quantified as described previously [16] . Results were expressed as area of necrotic core per lesion.
Immunohistochemistry Paraffin sections of aorta were stained for vascular cell adhesion molecule-1 (VCAM-1; 1:250 dilution; BD Pharmingen, San Diego, CA, USA), as described previously [17] . Positive-stained sections were quantified using Image-Pro Analyser 7.0 (Media Cybernetics, Bethesda, MD, USA) and stained areas were expressed as either stained area (μm 2 ) or percentage of the total plaque area.
Quantitative real-time PCR analysis Expression of genes encoding several markers of DAA were analysed by quantitative real-time PCR (qPCR) using the Taqman System on an ABI Prism 7500 Sequence Detector (Applied Biosystems, Foster City, CA, USA) as described previously [11] . Gene expression was normalised to 18S mRNA and reported as relative ratio to the control group (either the non-diabetic mice or normal-glucose-treated cells), which was assigned an arbitrary value of 1.
Western blotting Proteins (10 μg) were electrophoresed on 10.5% acrylamide gels under reducing conditions. Western blot analyses were performed with primary antibodies to either AT 2 R (H-143, 1:1,000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or AT 1 R (N-10, 1:1,000 dilution; Santa Cruz) and assessed with appropriate secondary antibodies. The housekeeping protein, α-tubulin (Sigma-Aldrich) was included to demonstrate equal loading of protein samples. Blots were detected using an enhanced chemiluminescent detection kit (Sigma-Aldrich) followed by quantification by densitometry using Quantity-One 4.5.2 software (Bio-Rad Laboratories, Richmond, CA, USA).
Statistical analysis Data were analysed by one-way ANOVA using SPSS 20.0 software (IBM, St Leonards, NSW, Australia). Post hoc comparisons were performed among the various groups using Fisher's least significant difference method. Data are expressed as mean ± SEM, with p < 0.05 considered as statistically significant.
Results

Metabolic variables STZ-treated Apoe
−/− mice developed sustained hyperglycaemia over the 20 week experimental period with elevated blood glucose and HbA 1c levels (p < 0.01 vs non-diabetic mice). Diabetic mice showed reduced body weight and elevated levels of total plasma cholesterol and triacylglycerol (Table 1) . Neither treatment with C21 alone nor candesartan alone affected any of these variables in either non-diabetic (control) or diabetic mice. While C21 did not have any systemic haemodynamic effect in either normoglycaemic or hyperglycaemic groups, administration of candesartan alone and in combination with C21 significantly reduced blood pressure in diabetic mice.
Atherosclerotic plaque area En face analysis of the whole aorta revealed a twofold increase in plaque area in diabetic mice compared with their non-diabetic counterparts (p < 0.05) (Fig. 1 ). Similar findings were also observed in the aortic arch and thoracic and abdominal segments. C21-treatment significantly reduced atherosclerotic lesion area in diabetic mice (p < 0.05 vs diabetic mice). While a similar reduction was seen with candesartan treatment alone, there was no further decrease seen in diabetic mice co-treated with C21 and candesartan. Importantly, C21 had no effect in modulating plaque lesion in non-diabetic mice.
Sinus plaque content Diabetic mice demonstrated a twofold increase in lipid deposition compared with their non-diabetic counterparts ( C21; p = 0.05 vs diabetic mice treated with candesartan alone). However, C21 had no effect in modulating lipid content within the intimal layer of the aortic sinus in non-diabetic mice.
Macrophage infiltration Immunohistochemically stained aortic sections from diabetic mice demonstrated a significant increase in CD68 protein expression ( Fig. 2b ; p < 0.01 vs nondiabetic mice). Neither C21 nor candesartan treatment inhibited diabetes-induced macrophage infiltration.
Aortic expression of AT 2 R and AT 1 R qPCR analysis performed on mouse aorta confirmed the expression of both AT 2 Rs and AT 1 Rs. mRNA levels of At 2 r (also known as Agtr2) were significantly upregulated in diabetic mice (p < 0.05 vs non-diabetic mice; Fig. 3a ) but were not modulated by C21, candesartan or C21 + candesartan treatment. In contrast, no significant difference in At 1 r (also known as Agtr1) gene expression was observed when comparing the non-diabetic and diabetic mouse groups (Fig. 3b) . Moreover, At 1 r expression remained unchanged in all treatment groups.
Aortic expression of the adhesion marker VCAM-1 With the adhesion of monocytes to endothelial cells considered a critical step in the initiation and development of DAA, VCAM-1 expression was examined at both the gene and protein level. qPCR analysis revealed a significant upregulation in Vcam-1 (also known as Vcam1) gene expression in diabetic mice (p < 0.01 vs non-diabetic mice, Fig. 3c ). While C21 treatment appeared to induce a trend towards a reduction in Vcam-1 gene expression in diabetic mice, this AT 2 R agonist significantly inhibited diabetes-induced VCAM-1 expression at the protein level (p < 0.05 vs diabetic mice; Fig. 3d ). Conversely, a significant reduction in Vcam-1 mRNA and VCAM-1 protein expression was observed in diabetic mice treated with candesartan alone and in combination with C21. Nonetheless, both qPCR and immunohistochemical analyses demonstrated that combination therapy with C21 and candesartan produced no additive effect in further reducing diabetes-induced VCAM-1 expression, when compared with either treatment alone. Importantly, C21 had no effect in modulating VCAM-1 expression at the gene or protein level in nondiabetic mice.
Aortic expression of markers of oxidative stress, inflammation and fibrosis Expression of p47phox, NADPH oxidase (NOX)-1 and NOX-4 was determined as part of the assessment of oxidative stress, while that of monocytechemoattractant protein-1 (MCP-1) and TGF-β1 was examined to assess inflammatory and fibrotic pathways. Treatment with either C21 or candesartan significantly ameliorated diabetes-induced p47phox (also known as Ncf1), Nox1, Mcp-1 (Ccl2) and Tgf-β1 (Tgfb1) mRNA levels (p < 0.05 vs diabetic mice; Fig. 3e , f, h, i); with Nox4 expression this amelioration was produced by only C21 and not candesartan (Fig. 3g) . Co-administration of C21 and candesartan markedly inhibited the expression of all the analysed markers in diabetic mice (p < 0.05 vs diabetic mice) while again no synergistic effect was seen when compared with either therapy alone. Importantly, C21 did not influence any of the analysed markers in non-diabetic mice. (Fig. 4) . Administration of C21 significantly inhibited the upregulation of these high-glucose-induced markers dose dependently, being most effective at a concentration of 1 μmol/l in both cell populations. Moreover, C21 at this dose significantly inhibited Ang II-induced effects (Figs 5, 6 ). Strikingly, these protective effects of C21 were completely abolished by the AT 2 R antagonist, PD123319 in both cell types (Figs 5, 6 ). While C21 (1 μmol/l) had similar efficacy to that of candesartan (10 μmol/l), co-administration of C21 and candesartan produced no additive effect in inhibiting high-glucose-and Ang-II-induced ICAM-1, NOX-4, TGF-β and Ctgf expression (Figs 5, 6 ). Based on the similar efficacy of candesartan and C21 in attenuating the pathology of DAA, further delineation of the involvement of the AT 2 R with respect to the effects of the ARB were further studied in HAEC. Interestingly, candesartanmediated protective effects were blocked by the AT 2 R antagonist, PD123319 (Fig. 5) .
In vitro expression of AT 2 R and AT 1 R Western blot analysis confirmed the expression of both AT 2 R and AT 1 R in HAEC and THP-1 cells (Fig. 7) . Although AT 2 R protein expression was significantly elevated in cells cultured in the high-glucose condition, neither C21 nor the AT 2 R and AT 1 R inhibitors (PD123319 and candesartan, respectively) had any effect in modulating AT 2 R expression. In contrast, AT 1 R expression remained unchanged in all conditions (Fig. 7) . Importantly, both AT 2 R and AT 1 R protein expression remained unchanged in normal-glucose conditions (data not shown). Similar results were also observed at the gene level (electronic supplementary material [ESM] Fig. 1 ).
Discussion
AT 2 R activation is increasingly recognised to confer protective effects in numerous disease states including atherosclerosis [18, 19] , which is considered to be the major contributor to premature mortality and morbidity. However, the biological effects mediated by the AT 2 R with respect to DAA have not At the in vivo level in mice, C21 was found to significantly reduce aortic plaque deposition and plaque size, in association with its ability to reduce expression of key mediators of inflammation, oxidative stress and fibrosis in the aorta. Indeed, C21 at a relatively low dose was found to retard the progression of DAA with similar efficacy to that afforded by the AT 1 R antagonist candesartan, when continuously administered over a 20 week treatment period. Interestingly, co-administration of C21 and candesartan had no clear-cut additive effect in attenuating DAA when compared with either treatment alone. Nevertheless, these findings support the potential role for C21 in monotherapy for providing protection against the progression of DAA by inhibiting inflammation, oxidative stress and fibrosis, with the AT 2 R agonist affording similar vasoprotective properties to the AT 1 R antagonist. Consistent with our findings, in an experimental model of myocardial infarction, C21 was demonstrated to improve cardiac function and reduce infarct size with similar efficacy to that observed with candesartan alone [20] . Our additional findings that C21 had no effect in influencing metabolic control or blood pressure in diabetic mice suggest that the beneficial effects seen with this agent do not occur via effects on glycaemic control or via a direct systemic haemodynamic action.
These protective effects of C21 were further explored in a more mechanistic manner at the in vitro level, in two human cell lines considered to be involved in the development of atherosclerosis-endothelial cells and macrophages [21, 22] . C21 was found to significantly ameliorate markers of oxidative stress, inflammation and fibrosis in both high-glucoseand Ang II-stimulated HAEC and monocytes cultures, with similar efficacy to that of candesartan treatment. Strikingly, these protective effects of C21 were completely abolished by the AT 2 R antagonist PD123319, thereby confirming the protective actions of C21 occur via the AT 2 R. Nevertheless, with limited understanding and knowledge of the signalling pathways of the AT 2 R, it remains to be fully elucidated as to how C21 confers its benefits in diabetes. Our in vitro and in vivo studies have demonstrated that these effects of C21 are not dependent on cell type or species and emphasise the central role of C21 as an anti-inflammatory, antioxidant and antifibrotic agent. This is consistent with previous studies demonstrating the efficacy of C21 as a reno-protective agent in halting the progression of insulin-deficient diabetic nephropathy [11, 23] . Thus, these observations strengthen the notion that the AT 2 R agonist C21 may represent a novel therapy for the treatment of diabetes-associated complications, including both micro-and macrovascular complications.
Given the wide tissue distribution of the AT 2 R [24] , AT 2 R activation has been shown to be protective against numerous disease states including renal [25, 26] , neuronal [27] and pancreatic injury [28] . However, the role of this receptor in the cardiovascular system still remains poorly understood. Previous studies have variously demonstrated that the AT 2 R could exert a protective [6, [29] [30] [31] [32] [33] , detrimental [34] or neutral [35, 36] role in atherosclerosis. These conflicting reports on the atherosclerotic role of the AT 2 R may suggest that its actions are likely to be dependent on a number of factors. These include the severity of the disease, where the efficacy at which AT 2 R mediates its protective effects may be lost in severe chronic conditions [37] , the absence or presence of hyperglycaemia [34, 38] and the particular animal strain examined in the study [5] . More recently, the diverse cardiac response associated with the AT 2 R has also been shown to be dependent on the transcription factors with which it interacts. The ability of the AT 2 R to bind and facilitate the translocation of promyelocytic leukaemia zinc finger transcription factor to the nucleus has been shown to be implicated in driving its hypertrophic activity in response to Ang II [39] .
Nonetheless, findings in this study have demonstrated that C21-mediated AT 2 R activation is beneficial against DAA. Consistent with these end-organ protective effects, albeit in the non-diabetic setting, C21 has been shown previously to reduce myocardial fibrosis and vascular injury [8] , improve ventricular function [20] and promote vasodilatation [40] in experimental models of cardiovascular disease. Although both the AT 1 R and AT 2 R were found to be expressed in the human monocytes and aortic endothelial cells used in this study, C21 did not have any marked effects on expression of either receptor. This is consistent with the view that the agonist most likely mediates its actions by influencing post-receptor signalling pathways. Indeed, recent studies have demonstrated that AT 2 R inhibits AT 1 Rmediated effects by targeting its downstream effectors, including TGF-β1 [41] and NOX [29] , as well as its ability to activate vasoconstriction inhibiting factor, an endogenous co-factor of Ang II [42] . Moreover, with previous studies demonstrating that AT 2 R forms a heterodimer receptor complex with AT 1 R to block the signalling and mediated functions of the latter [43] , it is possible that some of the Based on our findings that C21 exhibits similar antiatherogenic efficacy as candesartan and that the effects of candesartan could be inhibited in the presence of the AT 2 R antagonist PD123319, this could indicate that candesartanmediated actions occur at least in part as a result of the unopposed action of the AT 2 R. Consistent with these findings are studies, albeit in the non-diabetic setting, where candesartanmediated reduction of infarct size in pigs [44] and inhibition of cardiac remodelling in rats [45] were found to be dependent on AT 2 R activation. Furthermore, it is possible that AT 1 R blockade and AT 2 R agonism are acting through similar signalling pathways. Indeed, several studies have demonstrated that candesartan and C21 inhibit the mitogen-activated protein kinase pathway and signal through a nitric oxide-dependent pathway to mediate their cardioprotective effects [30, 46, 47] .
Pilot studies have suggested that C21 can antagonise the thromboxane receptor (TxR) [48] . Since a TxR antagonist has been shown to reduce atherosclerosis in a similar diabetic apolipoprotein E model [49] , one cannot exclude the possibility that the anti-atherosclerotic actions of C21 could involve the TxR. It remains to be determined whether this is a direct effect of C21 or involves an indirect action via the AT 2 R.
Future studies are warranted to further elucidate interactions between AT 1 R and AT 2 R, particularly in cells/organs that co-express the two Ang II receptors, and to identify potential effectors that are involved in mediating the activity of the AT 2 R. Our additional finding that AT 2 Rs were upregulated during diabetes could explain why the agonist did not affect aortic function under normal physiological conditions and only displayed its protective effects in DAA. Moreover, recent studies demonstrate that the AT 1 R undergoes desensitisation in response to prolonged exposure to its ligand and that the AT 2 R is unable to recruit β-arrestins, thereby contributing to the receptor subtype not being desensitised in the same manner as AT 1 R [50] . Hence, this allows C21 to have comparable long-term effects (compared with ARB) in exerting its protective effects, presumably via the AT 2 R. Taken together, these findings further highlight the advantage of C21 as a potential alternative therapy for DAA.
In conclusion, this study has clearly demonstrated that diabetes-related atherosclerosis can be influenced by approaches that target the two angiotensin receptor subtypes. These findings have important clinical significance in providing insight into potential therapeutic agents targeting the RAS that can be developed to halt the progression of DAA. Treatment with C21 as a monotherapy has been shown to retard the development of aortic atherosclerosis, particularly since it leads to suppression of the underlying oxidative stress, inflammation and fibrosis associated with insulin-deficient DAA. Furthermore, C21 was found to inhibit DAA-induced pathology to an extent similar to that produced by an ARB, suggesting that C21 may provide an alternative therapy for retarding DAA. Further elucidation of the signalling pathways that are activated by C21 would represent a crucial step in determining the strengths and limitations of this AT 2 R agonist as a therapeutic agent in treating the vascular complications of both type 1 and type 2 diabetes.
